Current lentiviral vector systems (the third generation) generate virus particles using four plasmids and a producer cell line. The rationale behind four plasmids is to enhance safety, as ...

As the particles are often pseudotyped with the envelope of the vesicular stomatitis virus (VSV), the vector ... Life Technologies Inc.) in which recombination occurs through the attR1 and attR2 and ...

The popularity of viral vector-based gene therapies and vaccines is rapidly ... Download this application note from Thermo Fisher Scientific to learn how scientists have used their lentiviral ...

AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its lentiviral vector platform. The deal will see AstraZeneca scoop up all ...